Evoke Pharma Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
SG&A Expense
2,601.80
13,150.00
11,818.30
10,544.40
11,230.70
8,014.70
EBIT
2,601.80
13,150.00
11,818.30
10,544.40
11,230.70
8,014.70
Unusual Expense
82.00
-
-
597.60
1,005.30
433.40
Non Operating Income/Expense
-
-
-
533.70
-
-
Interest Expense
159.90
107.80
303.20
268.00
-
-
Pretax Income
2,836.50
13,247.70
12,121.50
10,748.50
12,229.50
7,566.10
Consolidated Net Income
2,836.50
13,247.70
12,121.50
10,748.50
12,229.50
7,566.10
Net Income
2,836.50
13,247.70
12,121.50
10,748.50
12,229.50
7,566.10
Net Income After Extraordinaries
2,836.50
13,247.70
12,121.50
10,748.50
12,229.50
7,566.10
Net Income Available to Common
2,836.50
13,247.70
12,121.50
10,748.50
12,229.50
7,566.10
EPS (Basic)
1.20
2.20
1.87
1.15
0.82
0.46
Basic Shares Outstanding
2,368.00
6,032.60
6,485.80
9,338.10
14,897.90
16,602.40
EPS (Diluted)
1.20
2.20
1.87
1.15
0.82
0.46
Diluted Shares Outstanding
2,368.00
6,032.60
6,485.80
9,338.10
14,897.90
16,602.40
EBITDA
2,601.80
13,150.00
11,818.30
10,544.40
11,230.70
-
Non-Operating Interest Income
7.20
10.20
-
-
6.50
15.20
About Evoke Pharma
View Profile
